Daniel Kristensen

Daniel Kristensen is a Clinical Assistant Professor at Aalborg University, affiliated with the Department of Clinical Medicine and the Department of Haematology within The Faculty of Medicine. He holds an MD and is a PhD student conducting research in hematology and oncology. His work focuses on acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), and the effects of drugs like venetoclax and metformin in cancer treatment and prevention.

Research Interests include:

• Clinical outcomes of AML patients with extramedullary disease
• Population-based cohort studies analyzing treatment impacts
• Metformin's role in reducing blood cancer risks
• Health equity in clinical trial access
• Cultural and geographic barriers in healthcare

Recent studies highlight his work on metformin's potential as a chemopreventive agent for MPN, published in Blood Advances and widely covered in 29 news outlets. His 2025 studies on AML treatment outcomes and clinical trial equity appeared in Haematologica and British Journal of Haematology.

Collaborations span international teams, with publications often involving Danish colleagues from Aalborg University Hospital. He actively engages in public communication through media coverage of breakthrough findings.